Advances in therapy for hepatitis C infection

The first approved therapy for chronic hepatitis C virus (HCV) infection was recombinant interferon. Subsequently, controlled studies demonstrated that the combination of interferon-α and ribavirin leads to significantly higher virologic sustained responses in patients with chronic hepatitis C. A no...

Full description

Saved in:
Bibliographic Details
Published in:Microbes and infection 2002-10, Vol.4 (12), p.1237-1246
Main Authors: Zein, Claudia O, Zein, Nizar N
Format: Article
Language:English
Subjects:
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Antiviral Agents - pharmacokinetics
Antiviral Agents - therapeutic use
Biological and medical sciences
Biomedical Research
Hepatitis C
Hepatitis C - drug therapy
Hepatitis C - prevention & control
Herpes Simplex - diagnosis
Herpes Simplex - drug therapy
Herpes Simplex - prevention & control
Humans
Interferons - pharmacokinetics
Interferons - therapeutic use
Medical sciences
Pharmacology. Drug treatments
Therapy
Viral hepatitis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The first approved therapy for chronic hepatitis C virus (HCV) infection was recombinant interferon. Subsequently, controlled studies demonstrated that the combination of interferon-α and ribavirin leads to significantly higher virologic sustained responses in patients with chronic hepatitis C. A novel modification of the interferon molecule resulted in the formulation of pegylated interferons, which have a longer half-life than standard interferon. Two recent trials have established the superiority of pegylated interferons compared with interferon-α in inducing sustained virologic responses in patients with chronic HCV infection, with or without cirrhosis. Presumably, pegylated interferons will replace standard interferon in treating HCV infection. Phase 3 trials of pegylated interferons in combination with ribavirin are currently under way. Noninterferon-based therapies for the treatment of HCV infection are also in the developmental and experimental phases. Our aims in this review are to present the currently available therapeutic options for HCV infection and the evidence supporting their use in typical patients with chronic hepatitis C or in patients with special circumstances. We also briefly review novel therapeutic approaches, including noninterferon-based therapies.
ISSN:1286-4579
1769-714X
DOI:10.1016/S1286-4579(02)01651-9